Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Conjupro Biotherapeutics, Inc.
Conjupro Biotherapeutics, Inc.
PMV Pharmaceuticals, Inc
BeOne Medicines
Monte Rosa Therapeutics, Inc
Neonc Technologies, Inc.
AstraZeneca
MacroGenics
MacroGenics
ImmunityBio, Inc.
Hoffmann-La Roche
DualityBio Inc.
Incyte Corporation
Janux Therapeutics
Novelty Nobility, Inc.
Hangzhou DAC Biotechnology Co., Ltd.
Pfizer
Incyte Corporation
A2 Biotherapeutics Inc.
Incyte Corporation
Telix Pharmaceuticals (Innovations) Pty Limited
Marengo Therapeutics, Inc.
TransThera Sciences (Nanjing), Inc.
Klus Pharma Inc.
Theratechnologies
Cofactor Genomics, Inc.
Seagen Inc.
Cybrexa Therapeutics
Sotio Biotech Inc.
Carisma Therapeutics Inc
Travera Inc
AstraZeneca
Salubris Biotherapeutics Inc
Merck Sharp & Dohme LLC
Xencor, Inc.
TransThera Sciences (Nanjing), Inc.
Exelixis
HiberCell, Inc.
Evopoint Biosciences Inc.
Fate Therapeutics
Xencor, Inc.
Xencor, Inc.
Incyte Corporation
Genocea Biosciences, Inc.
Bayer
Incyte Corporation
Gilead Sciences
Incyte Corporation
SpeciCare
Incyte Corporation
Advanced Accelerator Applications